Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. (Q40357536)
Jump to navigation
Jump to search
scientific article published on 17 January 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. |
scientific article published on 17 January 2006 |
Statements
1 reference
Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. (English)
1 reference
1 reference
D Schadendorf
1 reference
S Ugurel
1 reference
B Schuler-Thurner
1 reference
F O Nestle
1 reference
A Enk
1 reference
E-B Bröcker
1 reference
S Grabbe
1 reference
W Rittgen
1 reference
L Edler
1 reference
A Sucker
1 reference
C Zimpfer-Rechner
1 reference
T Berger
1 reference
J Kamarashev
1 reference
G Burg
1 reference
A Tüttenberg
1 reference
J C Becker
1 reference
P Keikavoussi
1 reference
E Kämpgen
1 reference
G Schuler
1 reference
DC study group of the DeCOG
1 reference
17 January 2006
1 reference
1 reference
1 reference
Identifiers
1 reference